As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
The ongoing research activities to develop novel targeted therapies by the biopharmaceutical companies are expected to aid the industry growth in the coming years, for instance, CTI BioPharma Corp (NASDAQ: CTIC) is studying Oral Pacritinib use in myelofibrosis treatment, while Gilead Sciences, Inc. (NASDAQ: GILD) is developing a molecule- CYT387 for treating primary myelofibrosis. Moreover, the growing investments by the governments to enhance the healthcare infrastructure, particularly in the developing nations like China and India are expected to further boost the market growth.
The introduction of enhanced reimbursement policies and growing investments to create awareness regarding cancer treatment by various government and private organisations are further propelling the industry growth. Incyte Corporation (NASDAQ: INCY), a leading player in the industry, offers a comprehensive patient assistance programme, IncyteCARES (Connecting to Access, Reimbursement, Education and Support) to connect patients with support and resources during the treatment with Jakafi, further offering access to trained nurse professionals and financial support and other resources for eligible patients. Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration for treatment of people with intermediate or high-risk myelofibrosis, which is marketed by Incyte in the United States and by Novartis as Jakavi® (ruxolitinib) in the regions outside the United States.
Market Breakup by Drug Type, Treatment Type, End Use, and Regions:
Key Findings of the Report:
Key Offerings of the Report:
The major players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Eli Lilly and Company, and Gilead Sciences, Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.